AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04043052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychological evaluation
Description: Psychological evaluation including: MINI (current diagnosis) ; HDRS ; MDQ ; GAD-7 ; PC-PTSD-5 ; Quality of Sleep (item 6 of the Pittsburgh Sleep Quality Index) ; CES-D ; BAI ; RRS-short form ; IES-R ; mYFAS2.0;
Study NCT04043052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional evaluation
Description: Functional evaluation including : EQ5-D ; MFI ; LUNS ; SSQ ; Physical activity (IPAQ)
Study NCT04043052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional evaluation
Description: Functional evaluation including : EQ5-D ; MFI ; LUNS ; SSQ ; Physical activity (IPAQ)
Study NCT02239458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Study NCT04177693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG)
Description: 800 mg (4 capsules) of EGCG (green tea extract), taken orally on a daily basis for up to 2 months
Study NCT04177693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: 100 mg for 5 days
Study NCT04177693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 5 mg for 5 days
Study NCT00883571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: house advancement flap group
Description: A house flap of healthy tissue was incised to the depth of ischiorectal fat. The flap consisted of skin and subcutaneous tissue. The flap was sufficiently mobilized without undermining its fatty base containing perforating blood vessels. The flap should be loose and easily advanced into the anal canal. When the ''base'' of this house-shaped flap was advanced into the anal canal defect, it was fixed to the top of the excised area with 3/0 Vicryl sutures.
Study NCT00883571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rhomboid flap GROUP
Description: A rhomboid flap was incised in ischeorectal fossa and was mobilized without undermining of its fatty base into the anal canal so that the tip of rhomboid flap is sutured to the top of stricured area using vicryl 3/0.
Study NCT00883571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Y-V anoplasty GROUP
Description: Y-V anoplastyis performed by making a v shaped incision in the perianal skin posteriorly starting from the lower end of the wound resultant from excision of scared area. A V-shaped flap is then dissected with preservation fatty base .The V flap is then advanced into the anal canal so that its tip is sutured to the top of structured area using vicryel 3/0.
Study NCT02259530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Psychotherapeutic Intervention
Description: Evidence-based standard tools for the treatment of PTSD and comorbid khat dependence: Community Reinforcement Approach, Relapse Prevention, Narrative Exposure Therapy
Study NCT04043052 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological assessment
Description: Biological assessment : White and red blood cells count ; platelets count ; Haemoglobin ; CRPus ; Glycaemia ; Plasmatic HbA1c ; Plasmatic LDLc ; HDLc and triglyceride ; Creatinin clearance, Transaminases.
Study NCT04043052 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological assessment
Description: Biological assessment : White and red blood cells count ; platelets count ; Haemoglobin ; CRPus ; Glycaemia ; Plasmatic HbA1c ; Plasmatic LDLc ; HDLc and triglyceride ; Creatinin clearance, Transaminases.
Study NCT04043052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment
Description: During 3 months after inclusion, a 3 to 5 minutes daily interview will administer questions concerning mood symptoms, activities, stress experience, substance use, social relationships and medication intake, activities, social interaction, environmental conditions, experience of depressed mood, anhedonia, changes in weight, appetite, sleep, fatigue, feelings of worthlessness or inappropriate guilt, concentration or decision-making difficulty
Study NCT00633295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMN107- NILOTINIB
Description: The dose of nilotinib will be 400 mg bid.
Study NCT03042806 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: questionnaire
Description: all the COPD patients will be ask to complete the questionnaire
Study NCT02731092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: Bovine Lactoferrin 100 mg/ml dissolved in sterile water
Study NCT03726359 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiation Therapy
Description: Initial starting dose will be 7 Gy x5= 35 Gy delivered to the planning target volume (PTV). Radiotherapy will be delivered every other day so that the SBRT schedule is completed within 1.5-2 weeks.
Study NCT03238001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCTclock
Description: DCTclock is a quick and non-invasive test that measures cognitive function based on a computerized algorithmic analysis of the entire drawing process and output of a well-established cognitive assessment called The Clock Drawing Test (CDT).
Study NCT02021435 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: salt substitute
Description: Free salt substitute provided
Study NCT00770016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxin
Description: Dosage regulation will follow the local recommendations of treatment
Study NCT01762761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: TPO-R agonist
Study NCT01762761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03224468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Marijuana
Description: Patients in this group can choose when, where, and how much medical marijuana to use.
Study NCT04365036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: toripalimab 240mg, d1, intravenous drip
Study NCT02379338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Fluortriopride
Description: All subjects will receive a \[18F\]Fluortriopride PET/CT scan
Study NCT02545868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-PPV
Description: The 23-PPV vaccine will be given as a 0.5-milliliter (mL) intramuscular (IM) injection in the deltoid muscle on Day 112 (Group A) or Day 28 (Group B).
Study NCT02545868 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 23-PPV
Description: The 23-PPV vaccine will be given as a 0.5-milliliter (mL) intramuscular (IM) injection in the deltoid muscle on Day 112 (Group A) or Day 28 (Group B).
Study NCT02545868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-PCV Booster
Description: The 13-PCV booster will be given as an IM injection in the deltoid muscle on Day 140 (select participants in Group A).
Study NCT02545868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: The influenza vaccine will be given as an IM injection in the deltoid muscle at any time between Day 85 and Day 144 (select participants in Group A) or any time between Day 1 and Day 85 (Group B).
Study NCT02545868 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza Vaccine
Description: The influenza vaccine will be given as an IM injection in the deltoid muscle at any time between Day 85 and Day 144 (select participants in Group A) or any time between Day 1 and Day 85 (Group B).
Study NCT02545868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH
Description: KLH will be given as a 1-mg subcutaneous (SC) injection on Days 84, 112, and 140 (Group A) or Days 1, 28, and 56 (Group B).
Study NCT04365036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: pegaspargase, 2000U/m2, d1, intravenous drip
Study NCT02545868 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: KLH
Description: KLH will be given as a 1-mg subcutaneous (SC) injection on Days 84, 112, and 140 (Group A) or Days 1, 28, and 56 (Group B).
Study NCT02545868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCR
Description: OCR will be given as an intravenous (IV) infusion at a dose of 600 mg, with the first dose given as two infusions of 300mg 14 days apart, according to the specifications described in the corresponding Group A and Group B arms.
Study NCT02545868 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: OCR
Description: OCR will be given as an intravenous (IV) infusion at a dose of 600 mg, with the first dose given as two infusions of 300mg 14 days apart, according to the specifications described in the corresponding Group A and Group B arms.
Study NCT04365036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: pegaspargase, 2000U/m2, d1, intravenous drip
Study NCT04365036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: gemcitabine, 1000mg/m2, d1,d8, intravenous drip
Study NCT04365036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine, 1000mg/m2, d1,d8, intravenous drip
Study NCT04365036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: oxaliplatin, 130mg/m2, d1, intravenous drip,
Study NCT04365036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin, 130mg/m2, d1, intravenous drip,
Study NCT04365036 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Definitive intensity-modulated radiotherapy (IMRT)
Description: Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25\~26 days
Study NCT04365036 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Definitive intensity-modulated radiotherapy (IMRT)
Description: Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25\~26 days
Study NCT02545868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TT Vaccine
Description: The TT-containing adsorbed vaccine will be given as a 0.5-mL IM injection in the deltoid muscle on Day 85 (Group A) or Day 1 (Group B).
Study NCT02545868 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TT Vaccine
Description: The TT-containing adsorbed vaccine will be given as a 0.5-mL IM injection in the deltoid muscle on Day 85 (Group A) or Day 1 (Group B).
Study NCT01652872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period.
Study NCT01652872 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period.
Study NCT01652872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.
Study NCT01652872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.
Study NCT00426023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A 0,05% eye drop
Description: Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)
Study NCT00426023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketotifen fumarate 0.025% eye drops
Description: ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.
Study NCT04704414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exophthalmos measurement
Description: Exophthalmos measurement with iPhone 11 vs Artec Space Spider 3D Scanner vs Hertel Exophthalmometer.
Study NCT01557946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram
Description: citalopram 20-40 mg daily
Study NCT01793857 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Paper questionnaire
Study NCT02567422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV
Study NCT02567422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00457431 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mild therapeutic hypothermia
Description: Mild therapeutic hypothermia will be performed by any methods applicable in the hospitals
Study NCT01822964 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: targeted brain cooling (33°C) by RhinoChill device
Description: targeted brain cooling by Rhinochill device to 33°C tympanic temperature during TAVI procedure. After valve implantation, slow rewarming until 35.5°C
Study NCT02567422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT02567422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02567422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02567422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT02567422 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT03296189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls
Study NCT03296189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Phosphate
Description: intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls levobupivicaine and 2mls dexamethasone
Study NCT03296189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 10 mls normal saline
Study NCT03274700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin.
Description: Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
Study NCT03274700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo.
Description: Patients who will receive as placebo a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
Study NCT01038921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 8 mg dose of Melatonin
Study NCT01038921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01079221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity knee-extensor training
Description: High intensity aerobic knee-extensor exercise training, 4x 3 minutes interval training at \< 90 % of peak power, 3 days/week for 6 weeks
Study NCT01978119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSC
Description: Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
Study NCT01978119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
Study NCT02352493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-CC5
Description: Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
Study NCT02352493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: calculated volume to match active comparator
Study NCT02322606 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TAK-137 5 mg tablet, TAK-137 placebo tablet
Study NCT02322606 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet
Study NCT02322606 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TAK-137 5mg tablet, TAK-137 placebo tablet
Study NCT03590977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: licorice extract mouthwash
Description: mouth rinse that contains a natural herbal licorice root extract used as a preventive measure that reduce caries index.
Study NCT03590977 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: chlorohexidine mouthwash
Description: mouth wash that contains chlorohexidine as an active component
Study NCT00591812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ComPreSs Distal Femoral Replacement System.
Description: ComPreSs system of intramedullary fixation along with the Finn Knee system
Study NCT03632356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care Intervention (STEP)
Description: A stepwise progression of intervention according to the participant's response to the increasing levels of therapy. There will be 1 session of psychoeducation, followed by 5 sessions of Cognitive Behavioral Therapy (CBT) if panic symptoms do not improve at 1-month follow-up.
Study NCT03632356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Screening only
Description: Screening for probable panic attacks or panic disorder using the Structured Clinical Interview for DSM-5
Study NCT03749226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam lysine
Description: nebulization
Study NCT03749226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerogen Solo
Description: Aerogen's vibrating mesh technology, available within the Aerogen® Solo has been adopted for use of conventional mechanical ventilation. Aerogen Solo utilizes active vibrating mesh technology, where energy applied to the vibrational element, causes vibration of each of the 1000 funnel shaped apertures within the mesh. The mesh acts as a micropump drawing liquid through the holes producing a low velocity aerosol optimized for targeted drug delivery to the lungs. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) Aeroneb Solo showed an excellent aerosol delivery profile for Aztreonam lysine (AZLI) in an in vitro model of MV with short drug delivery time.
Study NCT03749226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CombiHaler
Description: The inhalation chamber CombiHaler™ spacer for mechanical ventilation and critical care (ICU) allows using both a vibrating mesh nebulizer such as Aeroneb ™, and a pMDI. It saves 50% of the nebulized drug when used in invasive ventilation. The inhalation chamber CombiHaler® is integrated on a circuit of a breathing device in invasive ventilation in particular for connexion of an Aeroneb® Pro or an Aeroneb® Solo. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) a better aerosol delivery performance (30%) was obtained using the Conbihaler spacer.
Study NCT02889549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month
Study NCT02889549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Standard dose of clopidogrel (75 mg, once daily, oral) treatment for 1 month
Study NCT00477711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab, cisplatin, capecitabine
Description: Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously
Study NCT02721589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A fully human monoclonal immunoglobulin (IgG4 subtype)
Study NCT01822964 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - current clinical practice, no cooling
Study NCT04264988 — intervention group
Intervention type: PROCEDURE
Intervention: Stopping of pelvic bleeding via several surgical methods
Description: Those surgical methods were pelvic packing, electrocautery, energy devices, suturing, fastener, muscle welding, procoagulant chemicals, and combination of those
Study NCT03957122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation~* 2000 pulses~* intensity of 110% resting motor threshold~* 10 sessions (daily from Monday to Friday)~* positioning of coil according to EEG position CP5/CP6